Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1LG2 | Q9BQ51 | 8/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 8/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | PRF1 | P14222 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2509721 | 0.85 | HTR4 (0.37) | HDAC6PRF1GAAMAPTTP53 | |
| SCHEMBL2512874 | 0.81 | HDAC6 (0.39) | HDAC6PRF1GAAMAPTTP53 | |
| SCHEMBL2509909 | 0.78 | GAA (0.41) | HDAC6PRF1GAAMAPTTP53 | |
| SCHEMBL2513409 | 0.76 | HDAC6 (0.39) | HDAC6PRF1GAAMAPTTP53 | |
| SCHEMBL2511385 | 0.74 | HDAC6 (0.38) | HDAC6PRF1CRBNKDM4EALDH1A1 | |
| SCHEMBL2510563 | 0.74 | IDH1 (0.38) | HDAC6PRF1GAAMAPTTP53 | |
| SCHEMBL2515759 | 0.74 | MAPT (0.45) | HDAC6GAAMAPTKDM4EALDH1A1 | |
| SCHEMBL2511407 | 0.74 | HDAC6 (0.41) | HDAC6PRF1GAAMAPTTP53 | |
| SCHEMBL2511620 | 0.72 | CRBN (0.37) | HDAC6PRF1CRBN | |
| SCHEMBL2514240 | 0.72 | IDH1 (0.40) | HDAC6PRF1GAAMAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8664214-B2 | Small molecule potentiators of metabotropic glutamate receptors I | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-03-04 | — | — | US | disclosed |
| US-20110245232-A1 | NOVEL SMALL MOLECULE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS I | ABBOTT GMBH & CO. KG (DE) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245232-A1 | NOVEL SMALL MOLECULE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS I | GRM3, GRIN2C, GRIN2B | PDCD1LG2 4370/4885CD274 4707/4885HDAC6 2366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.